UNSPSC 51352426: Estradiol/norethindrone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352426 Estradiol/norethindrone, a Commodity code, covers pharmaceutical procurement for state and local health systems and benefits programs, specifically hormone replacement therapies and contraceptives in multi-source generic formulations. State and local governments procure this product primarily through health and human services departments, cooperative purchasing alliances, and Medicaid/state employee benefit programs. The scope of work involves supplying generic estradiol/norethindrone products in compliance with FDA requirements, cGMP manufacturing practices, and the Drug Supply Chain Security Act, often with mandatory distribution through established pharmaceutical wholesalers. Issuing bodies include state health departments, multistate cooperative purchasing consortia administering benefits for state employees and subordinate jurisdictions, and state pharmacy benefit programs.

Recent activity centers on the upper Midwest and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for state and local facilities across Minnesota, Oregon, and other participating jurisdictions—a two-year contract with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on EDI capability, administrative fee compliance, and data format requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers outside traditional PBM and wholesaler channels. Vendors responding to MMCAP must maintain contractual relationships with at least two of three authorized wholesalers and certify cGMP and DSCSA compliance; the Texas RFI, as a preliminary market-intelligence tool, does not yet specify formal award criteria or budget parameters.